Lightstone Ventures

Investor type Venture Capital

Overview

Unlock datapoints

Portfolio analytics

Team

Investments

News & Media

Add fund to favorites
info
Save this fund for later to form your own custom list of funds
This summary is composed by our algorithm based on the analysis of the deals. If you think that some of this information is not accurate, please let us know about it and provide any supporting evidences if possible. Such cases will be analyzed by our ML-algorithm and implemented in our database, which will improve this summary.
Total investments 46
Average round size
info
The average size of a deal this fund participated in
$42M
Portfolio companies 29
Rounds per year 5.11
Lead investments 8
Follow on index
info
How often the fund supports its portfolio startups at next rounds
0.37
Exits 8
Key employees 5
Stages of investment
Early Stage Venture

Areas of investment

  • Biotechnology
  • Health Care
  • Therapeutics
  • Medical
  • Biopharma
Summary

In 2012 was created Lightstone Ventures, which is appeared as VC. The venture was found in North America in United States. The main office of represented VC is situated in the Menlo Park.

We also calculated 5 valuable employees in our database.

Among the most popular portfolio startups of the fund, we may highlight Earlens Corporation, Bold Penguin, Locana. We can highlight the next thriving fund investment areas, such as Pharmaceutical, Medical Device. The fund has no exact preference in some founders of portfolio startups. If startup sums 5+ of the founder, the chance for it to be financed is low. For fund there is a match between the country of its foundation and the country of its the most frequent investments - United States. Besides, a startup requires to be at the age of 4-5 years to receive the investment from the fund.

The standard case for the fund is to invest in rounds with 5-6 partakers. Despite the Lightstone Ventures, startups are often financed by New Enterprise Associates, Advanced Technology Ventures, Vertex Ventures HC. The meaningful sponsors for the fund in investment in the same round are Vertex Ventures HC, Atlas Venture, Windham Venture Partners. In the next rounds fund is usually obtained by New Enterprise Associates, Vertex Ventures HC, Windham Venture Partners.

Speaking about the real fund results, this VC is 15 percentage points more often commits exit comparing to other organizations. Comparing to the other companies, this Lightstone Ventures performs on 13 percentage points less the average number of lead investments. The fund is constantly included in 2-6 investment rounds annually. The higher amount of exits for fund were in 2016. The usual things for fund are deals in the range of 10 - 50 millions dollars. The top activity for fund was in 2019.

Read more

Related Funds

Funds investing in previous rounds
These funds often invest in the rounds preceeding the rounds of Lightstone Ventures:
Typical Co-investors
Lightstone Ventures is more likely to invest in rounds together with the following funds:
Funds investing in following rounds
These funds have a tendency to invest in the following rounds after Lightstone Ventures:

Funds with similar focus

Funds from United States
Funds with similar focus located in United States:
Funds with the same geo focus
Funds with similar geography of portfolio companies:

Look at other 50 related and similar funds Collapse list
Fund NameLocation
CenterSquare Investment Management Pennsylvania, Plymouth Meeting, United States
Lakehouse Ventures New York, New York, United States
Pirata Capital Management -
River Cities Capital Funds Cincinnati, Ohio, United States
Saltwater Ventures Cayman Islands, Midland
Souter Investments City of Edinburgh, Scotland, United Kingdom
The Poarch Band of Creek Indians Alabama, Atmore, United States
Underdog Labs -
Working Capital -
XinYue Equity -

Notable deals

CompanyIndustryRound SizeDateInvestorsLocation

Vigil Neuroscience

Biotechnology
$90M18 Aug 2021 Cambridge, Massachusetts, United States

WayCool

Agriculture
AgTech
Farming
Food and Beverage
Food Processing
$20M01 Apr 2021 Chennai, Tamil Nadu, India

Cyteir Therapeutics

Biopharma
Biotechnology
Pharmaceutical
$80M11 Feb 2021 Cambridge, Massachusetts, United States

Gemini Therapeutics

Biopharma
Biotechnology
Health Diagnostics
$95M08 Feb 2021 Cambridge, Massachusetts, United States

Ligature Therapeutics

Biotechnology
Medical
Therapeutics
$6M04 Jan 2021 Singapore, Central Region, Singapore

Atsena Therapeutics

Biotechnology
Health Care
Therapeutics
$55M16 Dec 2020 Durham, North Carolina, United States

Biotechnology
Health Care
Therapeutics
$100M14 Dec 2020 San Diego, California, United States

Tallac Therapeutics

Biotechnology
Health Care
Therapeutics
$62M01 Dec 2020 California, United States

Catamaran Bio

Biopharma
Biotechnology
$42M23 Nov 2020 Cambridge, Massachusetts, United States
News
Vigil Neuroscience Completes $90 million Series B Financing to Advance a Pipeline of Microglia-targeted Medicines to Treat Rare and Common Neurodegenerative Diseases

– Vigil Neuroscience, a biotechnology company harnessing the power of microglia for the treatment of neurodegenerative diseases, announced the completion of a $90m Series B financing to further advance Vigil’s proprietary pipeline of microglia-targeted medicines for the treatment of neurodegeneration.
– The financing was led by Vida Ventures with participation from existing investors Atlas Venture, Northpond Ventures and Hatteras Venture Partners as well as new investors including Surveyor Capital (a Citadel company), Cormorant Asset Management, Invus, OrbiMed, Rock Springs Capital, Deep Track Capital, Logos Capital, Pivotal bioVenture Partners, and Lightstone Ventures.

Alchemab Therapeutics Raises £60M in Series A Financing

– Alchemab Therapeutics from Cambridge, England, UK develops a platform that enables the identification of novel drug targets and therapeutics on the basis of patient B-cell antibody repertoires.
– The company raised £60m in Series A funding.
– The round was led by RA Capital Management, with participation from Lightstone Ventures, Data Collective VC (DCVC), DHVC, SV Health Investors and the Dementia Discovery Fund.
– The new investment will be used to advance the company’s target-agnostic drug discovery platform.

Review

  • No reviews are submitted yet.
Do you want more?
We provide dozens of additional datapoints about this fund.
Sign up and get access to full fund profile and advanced analysis.
Full team
Industries heatmap
Stages heatmap
Georgaphy breakdown
Coinvestors
Portfolio analysis
Performance indexes
Latest highlights
Unlock all data
Do you represent Lightstone Ventures?
Get access to manage this page
Get in touch
Found incorrect info? Let us know!

Wait!
You can raise money with us faster

Get matched with relevant funds

Find decision makers data

Connect with investors by email

Remind me later
...and save more than 200 hours*
*-Our recommendation and outreach system saves up to 200 hours of founder time on fundraising for seed and series A+ startups
We use LinkedIn only to verify your account. We don't import or message your contacts, nor post on your behalf.
By creating an account, you agree to our Terms of Service and Privacy Policy.
Crunchbase icon

Content report

The following text will be sent to our editors: